Subscribe Past Issues Translate ▼



### **INVEST LIKE A PRO, WITH THE PROS!**







Should you avoid the big banks and maybe even short them?

The <u>new Capital Ideas Digest</u> has the answers in a bullet point report from a well-respected bank analyst team.

Also, see research on a U.S. cannabis operator with the sector's "most experienced retail team in North America" and 120% upside.

Hey, have you see that the recently public *NextLeaf Solutions (CSE:OILS)* has nearly doubled on very heavy volume since we posted *our interview* last Monday?





Keep reading for news on the company, and about **another cannabis extraction company** whose CEO we just interviewed.

www.capitalideasmedia.com

## **Morning Need to Know**

Getting you ready for your investing day

April 17, 2019

Written & compiled by Mark Bunting, Publisher, Capital Ideas Media



## CANADIAN ANALYSTS' CALLS

#### INITIATIONS

Hexo (TSX:HEXO) gets started at "buy" with a target of \$10 (Canadian) by Bank of America Merrill Lynch (BOAML), which calls the Quebec-based company a "top pick in cannabis".

Aurora Cannabis (TSX:ACB;NYSE:ACB) and Canopy Growth (TSX:WEED:NYSE:CGC). BOAML starts coverage of these two with a "buy", as well, with respective targets of \$15 and \$70.

North American Construction Group (TSX:NOA) gets started at "outperformer" at CIBC with a price target of \$23. The stock closed Monday at \$12.17.

Athabasca Oil (TSX:ATH). CIBC starts coverage with an "outperformer" and a target of \$1.35. The stock closed yesterday at \$1.07.

\*\*

Valens GroWorks (CSE:VGW). Mackie Research resumes coverage with a "buy" and a price target of \$6 after assisting the company in raising more than \$43 million. The stock

closed Tuesday at \$3.70.

Valens CEO *Tyler Robson* tells us the issue was oversubscribed and that the company could have raised in excess of \$100 million.

See below for more information about our new video with Robson.

Organigram (TSXV:OGI). Mackie maintains a "buy" and moves the target to \$12.50 from \$10.75 after the company's quarterly earnings release.



### U.S. ANALYSTS' CALLS

Qualcomm (NASDAQ:QCOM) has been raised to "overweight" by JP Morgan on its leadership in 5G technology, and the fact Apple has dropped a long-running legal dispute and agreed to a multi-year deal with the chipset maker.

Netflix (NASDAQ:NFLX) gets its target raised to \$425 (U.S.) from \$400 by Stifel Nicolaus. See more below.

### STOCKS THAT MAY MOVE

NextLeaf Solutions (CSE:OILS) surged 19% on

Monday on volume of nearly 7 million shares after announcing it was raising \$2 million in a non-brokered private placement.

Clean Seed Capital (TSXV:CSX) dropped 11% after saying it would not go through with its acquisition of Harvest International.

Chorus Aviation (TSX:CHR). Chorus Aviation Capital has struck a deal to deliver five new Bombardier Q400 aircraft to SpiceJet of India under a sale and leaseback transaction. The company says:

"...CAC's portfolio will consist of 45 aircraft comprising 33 turboprops and 12 regional jets valued at approximately \$960 million (U.S.)."

Knight Therapeutics (TSX:GUD). In an escalating battle with the company Madison Biotec, which says it holds a 7.3% stake in GUD, issued a news release this morning saying:

"...an independent report authored by leading corporate governance expert Dr. Richard Leblanc reveals and confirms acute conflicts of interest and governance deficiencies at Knight."

Golden Star Resources (TSX:GSC;NYSE:GSS) say its president and CEO Sam Coetzer will be leaving the company as of April 30 and the board has appointed Andrew Wray to replace him.

Kraken Robotics (TSXV:PNG) says its Kraken Robotic Systems subsidiary has been awarded \$1 million from the Newfoundland and Labrador government, under the Innovation and Business Development Funding program.

CSX (NYSE:CSX) beat estimates as the railway company increased prices and contained costs.

Ericsson (NASDAQ; ERIC). The telecom equipment maker swung to a profit from a loss last year, beat estimates and raised its forecast.

ASML (NASDAQ:ASML). The chip equipment maker saw lower profit in its quarter but beat estimates, and forecast that growth would accelerate thanks in part to demand from Chinese chipmakers.

Netflix (NASDAQ:NFLX) beat estimates but its forecast for subscriber growth was below analysts expectations. The stock is higher.

ABB (NYSE:ABB) says its CEO of nearly six years has stepped down. No reason was given. The chairman will take over while ABB looks for a replacement.

#### **MARKETS**

The TSX and U.S. stock futures are indicating a positive open as China says its economy grew in

Q1 at a 6.4% clip, led by improvements in industrial production and consumer demand.

## **CURRENCIES**


The Canadian dollar is ticking up at \$0.7522 (U.S.) as it benefits from higher oil prices.

### **COMMODITIES**

West Texas Intermediate is near a high for the year partly on the China data at \$64.37 a barrel.

Gold is inching higher at \$1,278.50 an ounce.

# **Daily Update**



We'll be posting our conversation tomorrow with Valens GroWorks (CSE:VGW) CEO Tyler Robson.

Valens is the largest cannabis extractor in Canada, and has supply deals with Canopy Growth, Tilray, Organigram and others.

The company is gearing up for "Legalization 2.0" of edibles, infused beverages etc., when Valens' expertise will come to the fore.

Valens' **stock is up about 80**% since our <u>first</u> <u>interview</u> with Robson on our Legalization live

special. (Scroll to 28:00)

Please email questions, comments or concerns to:

customercare@capitalideasresearch.com

Access, ideas and insight.

Mark Bunting Publisher, Capital Ideas Media

www.capitalideasmedia.com















The information and recommendations made available here ("Information") by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any

losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don't consider buying or selling any stock without conducting your own due diligence.

Copyright © 2016 Capital Ideas Research, All rights reserved.

You are receiving this email because you are part of our investment network.

Add us to your address book

update subscription preferences